Platelet and Plasma Market Outlook - 2027
Human blood contains many chemical substances, primarily platelets, red blood cells, white blood cells and plasma. Platelet-rich plasma, also called PRP, is the part of the blood sample that includes mostly platelets and pure plasma, leaving out both the red and white blood cells. Platelet-poor plasma (PPP), as the name indicates, is similar to PRP in one way: it contains plasma. However, PPP contains almost no platelets. When collected and prepared correctly, human blood yields both PRP and PPP. Both platelet-poor plasma and platelet-rich plasma serve important functions in medical science. Both are used in the field of regenerative medicine. In areas as diverse as physical medicine, rheumatology, rehab and orthopedics, PRP and PPP therapy are used to speed up the human body’s natural healing process.
Covid-19 Scenario analysis:
The deadly coronavirus outbreak continues to spread worldwide with the number of positive cases and deaths rising expeditiously daily. The number of confirmed cases has touched the mark of 3.76 million with no signs of slowing down. Several vaccination trials are underway in different parts of the world. India is pitching plasma therapy as an effective mode of treatment. Country’s top medical research organization, Indian Council of Medical Research (ICMR), is framing a protocol to jump start this process. Convalescent plasma therapy is based on the concept of passive immunity, where antibodies of some disease developed in a person are used for treating others. Plasma in the blood contains antibodies, which helps to fight foreign pathogens. Once they have dealt with a certain kind of foreign element, some blood cells act as a memory cell and store information. When they come in contact with the same kind of pathogens again they identify and defect it quickly by producing the same antibodies. Hence the plasma market will see a boost during the pandemic as there is an increased need in the market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:
Drivers:
Multiple application of the PRP and PPP:
Platelet-rich plasma has several uses, all of which are derived from the substance’s high concentration of growth factors. These growth-enhancing chemicals are thought to greatly speed up the process of tissue repair in the human body. Platelets are also able to ramp up production of various types of fibroblasts, which is another assistive factor in healing process. Treatment with PRP appears to revive tendons that have been injured, attract blood to sites of injury, help with new cell recruitment, speed up growth of blood vessels, boost the nutritional profile of injury sites and generally promote healthful metabolic processes. Most of the known benefits of PRP therapy have been clearly demonstrated in animal studies by researchers who set out to test the efficacy of the treatment.
Platelet-poor plasma has a profound role in numerous medical treatments. One of the first known uses of PPP was in studies focused on platelet aggregation. Not only is PPP used as a scientific experiment control but it also serves as a precise mechanism to calibrate the concentrations of platelet-rich plasma samples. If, for example, a particular PRP sample contains too many platelets for a given treatment regimen, PPP can be added in specific amounts that render the PRP sample to be of the correct concentration. Additionally, PPP serves in its own right as a healing agent. Because PPP is thought to contain very high levels of fibrinogen, an agent known to speed up the healing of wounds. In cosmetic surgery, too, PPP plays a role. As a so-called “fibrin sealant,” PPP is currently utilized in orthopedic surgery, blood management and cosmetic surgery. One of the most advantageous aspects of PPP treatments is the fact that platelet-poor plasma is an abundant by-product in the preparation of PRP.
Regional and Market analysis:
According to the American Academy of Neurology, plasma can be used for the treatment of various neurological conditions. Plasma exchange process involves replacing plasma in a person’s blood. This process can be used for the treatment of conditions such as inflammatory dis-immune neuropathies, multiple sclerosis, myasthenia gravis, and other disorders will accelerate industry growth during the forecast period. Increasing blood transfusion rates in Europe will drive the platelet and plasma market growth over the forecast period. Blood transfusion process is primarily done to isolate the desired blood components such as red blood cells, plasma, platelets and other vital components of the blood. Government initiatives to create awareness regarding source plasma collection, as well as the use of lifesaving plasma protein therapies in rare diseases, will positively impact the market growth. Advancements in healthcare infrastructure coupled with the increasing number of blood transfusions will directly impact the growth of Platelet, Plasma Market in the coming years. The advent of technologically advanced platelet and plasma products is another major driver that will augment the market growth. Use of platelets and plasma in the treatment of rare, debilitating, life-threatening conditions and chronic diseases such as Hepatitis B heavily influences the growth of the market. Plasma-derived from blood can be used in treating rare diseases wherein no other alternative treatment is available. For instance, use of plasma for treatment of Ebola virus during its outbreak in West Africa. These factors are projected to augment the market growth during the forecast period.
Restrains:
The main indication for the transfusion of plasma is to correct deficiencies of clotting factors, for which a specific concentrate is not available, in patients with active bleeding. The products available are: fresh-frozen plasma (FFP), plasma that has undergone viral inactivation with solvent/detergent treatment (S/D FFP), with methylene blue (MB FFP) or with psoralens, in particular amotosalen (S59) and light; inactivation technology using riboflavin will soon be available until than this will hamper market.
Key benefits of the report:
- This study presents the analytical depiction of the global Platelet and Plasma industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Platelet and Plasma market share.
- The current market is quantitatively analyzed to highlight the global Platelet and Plasma market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Platelet and Plasma market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Platelet and Plasma Market research report:
- What are the leading market players active in the Platelet and Plasma market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Platelet And Plasma Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | T-Biotechnology (T-LAB), BCT, Inc, Stryker, DR. PRP AMERICA, LLC, Terumo, Glofinn Oy, EmCyte Corporation, Zimmer Biomet, DePuy Synthes, Arthrex, Inc |
 Other Players | Johnson and Johnson |
Loading Table Of Content...
